CMPS — COMPASS Pathways plc

Nasdaq · Health Care · Pharmaceuticals · CIK 1816590 ·
Last close
$11.35
Market Cap
$1.53B
52W High
$15.40
52W Low
$8.76
ADV30
4,213,441
Next earnings
2026-08-05
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -40,427,000 91,202,000 531,739,000 466,010,000 205,052,000
Dec 2025 0 -58,864,000 -93,878,000 210,349,000 149,608,000 263,197,000
Sep 2025 0 -36,612,000 -137,717,000 255,607,000 185,937,000 218,016,000
Jun 2025 0 -38,646,000 -38,403,000 293,536,000 221,881,000 130,981,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-159,519,000
Investing CF
$0
Financing CF
$362,807,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.15
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-731,392,000
Inventory
Receivables
$15,130,000
ST Investments
EBIT TTM
$-176,776,000
Pretax Income TTM
$-181,634,000
Interest Exp TTM
$4,858,000
Analysts
15

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -175,290,000 -287,862,000 210,349,000 263,197,000 -157,240,000
Dec 2024 0 -157,108,000 -155,122,000 213,666,000 58,971,000 -119,186,000
Dec 2023 0 -124,044,000 -118,464,000 275,987,000 50,243,000 -97,376,000
Dec 2022 0 -95,979,000 -91,505,000 197,294,000 16,014,000 -105,451,000
Dec 2021

TTM Snapshot

Revenues TTM
$1,977,000
NetIncome TTM
$-54,351,000
OpCashFlow TTM
$0
Assets (Latest)
$213,666,000
Forward EPS
$-1.34

Max Pain — expiry 2026-08-21

max pain strike: $11.00 · spot: $11.35 · call oi: 34,309 · put oi: 16,231
Expected Move to 2026-08-21: ±$2.20 (19.38%) — implied range $9.15$13.55 · ATM straddle on $11.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TRAX First Tracks Biotherapeutics, Inc. $1.54B $44.04
INVA Innoviva, Inc. $1.55B $20.97
SEPN Septerna, Inc. $1.55B $34.45
XNCR Xencor Inc $1.50B $20.21
MLTX MoonLake Immunotherapeutics $1.57B $18.44

News headlines (Yahoo Finance, 1h cache)

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
2026-07-29 10:30 · Yahoo
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
2026-07-29 09:20 · Yahoo
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
2026-07-27 14:38 · Yahoo
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
2026-07-22 17:25 · Yahoo
Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy
2026-07-17 16:50 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline Friday
2026-07-17 14:57 · Yahoo
COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD
2026-07-17 07:12 · Yahoo
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
2026-07-16 21:19 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
2026-07-16 15:16 · Yahoo
Why Psychedelic stocks are surging today
2026-07-16 11:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.